Mark S Cohen - Net Worth and Insider Trading
Mark S Cohen Net Worth
The estimated net worth of Mark S Cohen is at least $102,921 dollars as of 2024-05-27. Mark S Cohen is the Director of Akari Therapeutics PLC and owns about 52,780 shares of Akari Therapeutics PLC (AKTX) stock worth over $102,921. Details can be seen in Mark S Cohen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark S Cohen has not made any transactions after 2015-09-18 and currently still holds the listed stock(s).
Transaction Summary of Mark S Cohen
Mark S Cohen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark S Cohen owns 1 companies in total, including Akari Therapeutics PLC (AKTX) .
Click here to see the complete history of Mark S Cohen’s form 4 insider trades.
Insider Ownership Summary of Mark S Cohen
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AKTX | Akari Therapeutics PLC | 2015-09-18 | director |
Mark S Cohen Latest Holdings Summary
Mark S Cohen currently owns a total of 1 stock. Mark S Cohen owns 52,780 shares of Akari Therapeutics PLC (AKTX) as of September 18, 2015, with a value of $102,921.
Latest Holdings of Mark S Cohen
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics PLC | 2015-09-18 | 52,780 | 1.95 | 102,921 |
Holding Weightings of Mark S Cohen
Mark S Cohen Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark S Cohen has made a total of 0 transactions in Akari Therapeutics PLC (AKTX) over the past 5 years. The most-recent trade in Akari Therapeutics PLC is the acquisition of 52,780 shares on September 18, 2015, which cost Mark S Cohen around $200,564.
Insider Trading History of Mark S Cohen
- 1
Mark S Cohen Trading Performance
GuruFocus tracks the stock performance after each of Mark S Cohen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark S Cohen is -53.57%. GuruFocus also compares Mark S Cohen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark S Cohen within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark S Cohen's insider trading performs compared to the benchmark.
Performance of Mark S Cohen
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -48.49 | | | | | |
| Relative Return to S&P 500(%) | -52.32 | | | | | |
Mark S Cohen Ownership Network
Mark S Cohen Owned Company Details
What does Akari Therapeutics PLC do?
Who are the key executives at Akari Therapeutics PLC?
Mark S Cohen is the director of Akari Therapeutics PLC. Other key executives at Akari Therapeutics PLC include General Counsel and Secretary Robert M Shaw , director & 10 percent owner James Hill , and director & 10 percent owner Stuart Ungar .
Akari Therapeutics PLC (AKTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akari Therapeutics PLC (AKTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akari Therapeutics PLC (AKTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akari Therapeutics PLC (AKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akari Therapeutics PLC Insider Transactions
Mark S Cohen Mailing Address
Above is the net worth, insider trading, and ownership report for Mark S Cohen. You might contact Mark S Cohen via mailing address: C/o Celsus Therapeutics Plc, 24 West 40th Street, New York Ny 10018.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
